Shares of NASDAQ:TRIB opened at $0.95 on Thursday. The company has a debt-to-equity ratio of 2.09, a current ratio of 3.36 and a quick ratio of 2.07. Trinity Biotech has a 12 month low of $0.93 and a 12 month high of $4.01. The stock’s 50 day moving average price is $1.28 and its 200 day moving average price is $2.03.
Trinity Biotech (NASDAQ:TRIB) last posted its quarterly earnings results on Tuesday, August 20th. The company reported ($0.19) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of $0.07 by ($0.26). The business had revenue of $22.50 million during the quarter. Trinity Biotech had a negative return on equity of 8.96% and a negative net margin of 30.92%.
A hedge fund recently raised its stake in Trinity Biotech stock. Hunter Associates Investment Management LLC boosted its holdings in Trinity Biotech plc (NASDAQ:TRIB) by 33.0% during the 2nd quarter, according to the company in its most recent disclosure with the SEC. The fund owned 1,434,110 shares of the company’s stock after buying an additional 355,500 shares during the quarter. Hunter Associates Investment Management LLC owned 5.97% of Trinity Biotech worth $2,366,000 as of its most recent SEC filing. 49.17% of the stock is owned by hedge funds and other institutional investors.
About Trinity Biotech
Trinity Biotech plc acquires, develops, manufactures, and markets medical diagnostic products for the clinical laboratory and point-of-care (POC) segments of the diagnostic market. The company offers clinical laboratory products, including diagnostic tests and instrumentation, which detect infectious diseases, such as lyme disease, sexually transmitted diseases, respiratory infections, epstein barr virus, and other viral pathogens; and products for the in-vitro diagnostic testing for haemoglobin A1c used in the monitoring and diagnosis of diabetes, and identifying those who are at a high risk of developing diabetes.
Read More: Call Option
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for Trinity Biotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Trinity Biotech and related companies with MarketBeat.com's FREE daily email newsletter.